What should you know about glioblastoma immunohistochemistry?

After a biopsy or operation, a pathologist examines the tissue under a microscope and may apply antibody stains. Each stain attaches to a particular protein or cellular feature, creating a visible pattern. The pattern is interpreted alongside the cell appearance, imaging, clinical history, and other laboratory findings; one stain does not by itself describe the whole tumour.

Results may help distinguish glioblastoma from other brain tumours and may report markers relevant to tumour classification or treatment discussions. A report can contain technical terms, so the treating team should explain which findings are confirmed, which remain uncertain, and whether additional molecular testing is needed.

Keep a copy of the pathology report and ask which stains were performed, what each result means, and whether the sample was large enough for further testing. The team may combine immunohistochemistry with biopsy findings and brain scans before recommending surgery, radiotherapy, chemotherapy, or monitoring. Do not compare a single marker with someone else’s result without the surrounding diagnosis.

Contact the clinical team promptly for new or worsening weakness, trouble speaking, a seizure, repeated vomiting, severe headache, unusual sleepiness, or a sudden change in behaviour. After a biopsy, urgent assessment is also appropriate for increasing wound swelling, fever, fluid leakage, or a worsening neurological change.

Ask: Which immunohistochemistry findings support the diagnosis? Are any results pending? Could the findings alter treatment planning? Should the tissue undergo molecular testing? Who will explain the report and when will the multidisciplinary team discuss it?